Literature DB >> 7081354

A comparison of different cellular inocula in an experimental model of massive periretinal proliferation.

D M Fastenberg, K R Diddie, N Sorgente, S J Ryan.   

Abstract

We modified a preexisting experimental model of massive periretinal proliferation by injecting cells of differing origins into the rabbit vitreous cavity. These cells included autologous and homologous fibroblasts, homologous chondrocytes, homologous retinal pigment epithelial cells, heterologous bovine endothelial cells, and heterologous murine embryonal cells. All cell injections caused vitreous and retinal membrane formation that resulted in a process similar to massive periretinal proliferation. Clinically the character of the membranes formed and the time course in the development of traction retinal detachments was similar for all the different cell types. The initial cell dosage injected was the critical factor in determining the severity of the traction retinal detachments leading to massive periretinal proliferation.

Entities:  

Mesh:

Year:  1982        PMID: 7081354     DOI: 10.1016/s0002-9394(14)77369-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  32 in total

1.  Dispersion of retinal pigment epithelial cells from experimental retinal holes.

Authors:  S A Bishara; S M Buzney
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

2.  Growth factors outside the PDGF family drive experimental PVR.

Authors:  Hetian Lei; Gisela Velez; Peter Hovland; Tatsuo Hirose; Debra Gilbertson; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-25       Impact factor: 4.799

3.  Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53.

Authors:  Hetian Lei; Gisela Velez; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2011-02-28       Impact factor: 4.272

4.  Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Authors:  Steven Pennock; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2014-09-26       Impact factor: 4.307

5.  RasGAP Promotes Autophagy and Thereby Suppresses Platelet-Derived Growth Factor Receptor-Mediated Signaling Events, Cellular Responses, and Pathology.

Authors:  Hetian Lei; Cynthia X Qian; Jinghu Lei; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 4.272

6.  The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR).

Authors:  Khaled Nassar; Julia Lüke; Matthias Lüke; Mahmoud Kamal; Effat Abd El-Nabi; Mahmoud Soliman; Martin Rohrbach; Salvatore Grisanti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-07-07       Impact factor: 3.117

7.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

8.  Experimental study on drug therapy of "traction retinal detachment" after posterior penetrating eye injury in the rabbit.

Authors:  W Behrens-Baumann; M Vogel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

9.  Development of traction retinal detachments following intravitreal injections of retinal Muller and pigment epithelial cells.

Authors:  M A Peters; J M Burke; M Clowry; G W Abrams; G A Williams
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

10.  A novel function of p53: a gatekeeper of retinal detachment.

Authors:  Hetian Lei; Marc-Andre Rheaume; Jing Cui; Shizuo Mukai; David Maberley; Arif Samad; Joanne Matsubara; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.